Nilotinib
Nilotinib is a cancer drug that interferes with the growth and spread of cancer cells in the body. The treatment for Philadelphia chromosome-positive chronic myeloid leukemia, a kind of blood cancer, is nilotinib. Nilotinib is a transfer inhibitor whose targets are BCR-ABL, c-kit, PDGF, with the potential to treat various types of leukemia, including chronic myeloid leukemia.
Nilotinib inhibits the enzyme tyrosine kinase. Nilotinib binds to the inactive form of the Abl protein kinase domain and stabilizes it.
The maximum blood concentration is reached 3 hours after oral consumption. The stable concentration is reached within 8 days.
Bioavailability increases with simultaneous consumption with food (compared to the fasting state).
Therapeutic Fields
Dosage Form
Capsule 200mg
Mechanism of action
Nilotinib inhibits the enzyme tyrosine kinase. Nilotinib binds to the inactive form of Abl protein kinase domain and stabilizes it.
Uses of Nilotinib
Philadelphia positive chronic myeloid leukemia.
Method of Use
Adults: 400 mg orally twice daily in advanced and refractory chronic myeloid leukemia.
300 mg twice daily in newly diagnosed chronic myeloid leukemia.
We understand the complexities and challenges you face in the healthcare industry. That’s why we’re dedicated to providing innovative solutions and insightful knowledge to help you achieve your goals.
Your input is crucial in helping us understand your needs and deliver the most relevant support:
